AUTHORS
Yiyan Zhu, Wenzhi CAI, MD2, Jun Zhang3, Xinyue Zhang4, Dan Liu, MD5, Hongying Chao6, Depei Wu Sr, MD7, Suning Chen8
AFFILIATIONS
1 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
2 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
3 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
4 Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, Jiangsu, China
5 Soochow Hopes Hematonosis Hospital, Suzhou, Jiangsu, China
6 Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, Jiangsu, China
7 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
8 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
ABSTRACT
Introduction:
Tyrosine kinase inhibitors and blinatumomab have improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), yet persistent measurable residual disease (MRD) and relapse continue to limit transplantation-free treatment. Whether CD19 chimeric antigen receptor (CAR) T-cell consolidation during first complete remission (CR1) can provide durable disease control without allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain. We evaluated the effectiveness and safety of this strategy.
Methods:
In this multicenter retrospective real-world study, 574 patients with de novo Ph+ ALL treated between January 2016 and December 2025 were screened. The primary CAR T-cell cohort comprised 68 patients who achieved CR1, received frontline autologous CD19 CAR T-cell consolidation, and underwent no subsequent allo-HSCT. We assessed MRD by flow cytometry (FCM), BCR::ABL1 quantitative polymerase chain reaction (qPCR), and immunoglobulin/T-cell receptor gene rearrangement-based next-generation sequencing (IG/TR NGS) when paired samples were available. CAR T-cell expansion, relapse, survival, and adverse events were evaluated. Event-free survival (EFS) and overall survival (OS) were calculated from CAR T-cell infusion. For an exploratory, unadjusted comparison, EFS and OS were compared by log-rank testing with those of 34 contemporaneous patients who received frontline blinatumomab-based consolidation at the same participating centers.
Results:
The median age was 45 years (range, 17–65); 16 patients (23.5%) had extramedullary disease at diagnosis, and 42 (61.8%) remained in CR without a major molecular response after induction. Following CAR T-cell infusion, FCM-MRD negativity increased from 66.2% (45/68) to 76.5% (52/68), with 16 of 23 (69.6%) pre-infusion FCM-MRD-positive patients converting to negative. The complete molecular response (CMR) rate increased from 51.5% (35/68) to 77.9% (53/68), with 20 of 33 (60.6%) patients without pre-infusion CMR achieving CMR. Among 12 patients with paired IG/TR NGS-MRD data, MRD negativity increased from 66.7% (8/12) to 91.7% (11/12). The median peak CAR transgene copy number was 7.23 × 104 copies/μg DNA at a median of 9 days after infusion. At a median follow-up of 37.2 months, 3-year EFS, OS, and cumulative incidence of relapse were 87.7% (95% CI, 74.4–94.3%), 91.4% (95% CI, 78.4–96.8%), and 10.7% (95% CI, 1.7–19.8%), respectively. In the contemporaneous blinatumomab cohort (n = 34; median follow-up, 13.8 months), 1-year EFS and OS were 94.1% and 96.7%, respectively, versus 96.5% and 98.4% in the CAR T-cell cohort; survival curves did not differ significantly (log-rank P = 0.081 for EFS and P = 0.510 for OS). Seven patients (10.3%) in the CAR T-cell cohort relapsed, with no central nervous system (CNS) or other extramedullary relapses; five patients (14.7%) in the blinatumomab cohort relapsed, including one CNS and two non-CNS extramedullary relapses. In the CAR T-cell cohort, cytokine release syndrome (CRS) occurred in 28 patients (41.2%), all grade 1–2; no immune effector cell-associated neurotoxicity syndrome (ICANS) occurred.
Conclusions:
In this multicenter cohort, frontline CD19 CAR T-cell consolidation during CR1 was associated with substantial MRD deepening and durable disease control without subsequent allo-HSCT, with no grade ≥3 CRS and no ICANS. Although no significant survival difference was observed in the exploratory comparison with a smaller blinatumomab cohort with shorter follow-up, these findings support prospective comparative evaluation of CAR T-cell consolidation as a transplantation-free post-remission strategy for Ph+ ALL.
DISCLOSURES
Yiyan Zhu: No relevant conflicts of interest to declare.